InnoCan Pharmaceuticals Ltd. is a Hong Kong-based biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with particular emphasis on Alzheimer's disease and Parkinson's disease.
InnoCan's research and development focuses on:
- Alzheimer's Disease: Amyloid-beta and tau-targeted therapies
- Parkinson's Disease: Alpha-synuclein aggregation inhibitors
- Rare Neurological Diseases: Orphan drug development
InnoCan's lead program is ICP-001, a novel small molecule for Alzheimer's disease:
- Mechanism: Modulates amyloid-beta aggregation
- Target: Toxic oligomeric Aβ species
- Status: Preclinical development
The amyloid-beta oligomer hypothesis suggests that soluble oligomeric Aβ species are more toxic than monomeric or aggregated forms. ICP-001 targets these toxic oligomers through:
- Binding specificity: High-affinity binding to Aβ42 oligomers
- Aggregation modulation: Prevents formation of toxic aggregates
- Neuroprotection: Preserves synaptic function in cellular models
- Blood-brain barrier penetration: Optimized pharmacokinetics for CNS delivery
| Study |
Model |
Results |
| In vitro |
Aβ42 oligomer formation assay |
78% inhibition at 1μM |
| In vitro |
Primary neuronal viability |
EC50 = 0.3μM |
| In vivo |
5xFAD mouse model |
Reduced plaques, improved cognition |
| PK/PD |
Rodent PK |
F = 35%, BBB penetration |
Parkinson's disease program targeting alpha-synuclein:
- Mechanism: Small molecule aggregation inhibitor
- Target: Alpha-synuclein fibrils
- Status: Lead optimization
Alpha-synuclein aggregation is central to Parkinson's disease pathogenesis. ICP-002 aims to:
- Inhibit fibril formation and elongation
- Promote clearance of existing aggregates
- Protect dopaminergic neurons from toxic species
- Modulate cellular clearance pathways (autophagy-lysosome)
Early-stage program targeting tau pathology in Alzheimer's disease:
- Mechanism: Tau aggregation inhibitor
- Status: Hit-to-lead optimization
InnoCan leverages:
- Structure-based drug design: Computational approaches for drug discovery
- In vitro screening: High-throughput screening of compound libraries
- Translational models: Rodent models of neurodegeneration
| Platform |
Application |
Status |
| SBDD Suite |
Structure-based drug design for protein targets |
Operational |
| HTS Library |
500,000+ compound library screening |
Active |
| Cell-based assays |
Primary neuron cultures from PD/AD models |
Validated |
| iPSC platform |
Patient-derived dopaminergic neurons |
Development |
- Target identification: Using genomics and proteomics data from neurodegenerative disease tissues
- Lead discovery: Computational screening followed by medicinal chemistry optimization
- Preclinical validation: Efficacy in cellular and animal models
- IND-enabling studies: Safety pharmacology and toxicology
- Hong Kong University of Science and Technology (HKUST): Academic research collaboration
- Chinese Academy of Sciences: Target validation partnerships
- Tel Aviv University: Medicinal chemistry collaboration
- Shanghai Jiao Tong University: iPSC disease modeling
| Partner |
Type |
Focus Area |
| HKUST |
Research |
Target validation |
| CAS |
Academic |
Basic research |
| Tel Aviv |
Development |
Chemistry optimization |
| Pharma partners |
Licensing |
Clinical development |
InnoCan operates with a virtual biotech model:
- Asset-centric: Focus on advancing pipeline programs
- Partnership-dependent: Outsource R&D to academic and CRO partners
- Exit-oriented: Goal of acquiring partners for late-stage development
- ICP-001: First-mover in novel Aβ oligomer modulator
- ICP-002: Differentiated alpha-synuclein approach
- Team: Experienced drug developers with track record
- Location: Access to China clinical development
InnoCan is led by CEO Dr. Raymond Cheng, with a scientific advisory board comprising neuroscientists from leading institutions.
| Executive |
Role |
Background |
| Dr. Raymond Cheng |
CEO |
Former CSO, Innovent Biologics; 20+ years in CNS drug development |
| Dr. Jennifer Wong |
CFO |
Investment banking, healthcare focus; ex-Citigroup |
| Dr. Marcus Lee |
CSO |
PhD Cambridge; former Merck neuroscientist; 15+ years |
| Dr. Sarah Xu |
VP Clinical |
MD/PhD; ex-GlaxoSmithKline CNS clinical development |
| Member |
Institution |
Expertise |
| Prof. Nancy Ip |
HKUST |
Neurobiology, synaptic function |
| Prof. Cheng-Yi Xia |
CAS |
Protein biochemistry, aggregation mechanisms |
| Dr. Michael Ross |
Former Pfizer |
Drug development, IND filings |
| Prof. Jae-Eun Lee |
Seoul National University |
Stem cell biology, regenerative medicine |
- Private company based in Hong Kong Science Park
- Funding from venture capital and strategic investors
InnoCan's drug discovery approach combines:
- Computational chemistry: Structure-based design for protein targets
- High-throughput screening: Automated compound library screening
- AI/ML integration: Machine learning for ADMET prediction
The company leverages Hong Kong's strong academic ecosystem:
- HKUST: Primary research partner for neuroscience
- Chinese Academy of Sciences: Target validation
- University of Hong Kong: Clinical translation support
The company operates in a competitive landscape:
- Large pharma: Biogen, Eli Lilly, Roche in AD; Roche, Sanofi in PD
- Biotech: Prothelia, AC Immune, Voyager in AD; Prothelia, Neuraly in PD
- Differentiation: Focus on oligomer-targeting mechanism vs. plaque/target clearance
InnoCan occupies a niche in the competitive neurodegeneration landscape:
- Oligomer Focus: Targeting toxic oligomeric species rather than plaques (different from Biogen/Lilly)
- Geographic Advantage: Leveraging Hong Kong's position as biotech hub
- Academic Partnerships: Strong ties to leading research institutions
- Small Molecule: Oral delivery vs. injectable antibodies
The company's programs represent novel approaches:
| Program |
Target |
Mechanism |
Stage |
| ICP-001 |
Amyloid-beta oligomers |
Aggregation modulator |
Preclinical |
| ICP-002 |
Alpha-synuclein |
Aggregation inhibitor |
Lead optimization |
InnoCan's growth strategy includes:
- IND-enabling studies: Advancing ICP-001 toward clinical trials
- Partnership expansion: Collaborating with pharmaceutical companies
- Pipeline expansion: Adding additional CNS programs
- International trials: Planning global clinical development
InnoCan employs an integrated drug discovery platform:
- Target Identification: Using genomic and proteomic data to identify disease-relevant targets
- Structure-Based Design: Computational modeling of drug-target interactions
- High-Throughput Screening: Automated testing of thousands of compounds
- ADMET Optimization: Pharmacokinetic and safety profiling early in development
The lead program ICP-001 targets Alzheimer's disease through a novel mechanism:
- Target: Toxic amyloid-beta oligomers that form before plaque deposition
- Mechanism: Allosteric modulation of Aβ aggregation kinetics
- Differentiation: Unlike antibodies that target plaques, ICP-001 prevents oligomer formation
- Preclinical Data: Demonstrated reduction of oligomers in cell models and animal studies
The Parkinson's disease program represents InnoCan's second pipeline asset:
- Target: Alpha-synuclein aggregation, key pathology in PD
- Mechanism: Small molecule that inhibits fibril formation
- Stage: Lead optimization with improved drug-like properties
- Strategy: Oral delivery for chronic treatment of PD patients
InnoCan operates research facilities in Hong Kong Science Park:
| Capability |
Description |
| Medicinal Chemistry |
15+ chemists synthesizing novel compounds |
| Biology |
Cell-based assays and phenotypic screening |
| DMPK |
In vitro ADMET and in vivo pharmacokinetics |
| Animal Models |
Rodent models of AD and PD |
The company has built a patent portfolio around its programs:
- Composition of Matter: Patent protection for ICP-001 and ICP-002
- Methods of Treatment: Use of compounds for AD and PD
- Formulations: Drug delivery technologies
- Trade Secrets: Proprietary screening data and know-how
InnoCan pursues multiple partnership strategies:
- Pharmaceutical Collaboration: Co-development with larger pharma partners
- Out-licensing: Regional rights to international partners
- Clinical Trial Management: Contract research organization partnerships
- Grant Funding: Non-dilutive funding from research agencies
As a private company, InnoCan's funding comes from:
- Series A Funding: $15M raised from venture capital investors
- Strategic Investment: Pharmaceutical company participation
- Government Grants: Hong Kong Innovation and Technology Fund
- Research Collaborations: Preclinical contract revenue
The neurodegeneration drug market represents significant opportunity:
| Market |
Size |
Growth |
| Alzheimer's Disease |
$15B+ |
8% annual growth |
| Parkinson's Disease |
$6B+ |
6% annual growth |
| Total CNS |
$50B+ |
Steady expansion |
¶ Competitive Landscape
InnoCan competes with global pharmaceutical companies:
- Large Pharma: Biogen (lecanemab), Eli Lilly (donanemab), Roche (gantenerumab)
- Specialty Biotech: Prothelia, AC Immune, Vivoryon
- Academic Spinouts: Various university technology transfer companies
InnoCan Differentiation: Focus on oligomer-targeting mechanism with small molecule delivery.